AD4 for treatment for oxidatvie stress related diseases (Yissum)
Highlights:
The World Health Organisation predicts that by 2040, as a result of a growing ageing population, neurodegenerative diseases (NDDs) will have overtaken cancer to become the world’s second leading cause of death, after cardiovascular disease. However, governments and industry have yet to make a major commitment to treating NDDs.
Maintaining the balance of oxidants/antioxidants determines the redox-state in the body. Lowering oxidative stress appears to be a valid approach for treating redox related diseases including neurodegenerative diseases, asthma, and other chronic obstructive pulmonary diseases (COPD).
Current reducing reagents, such as vitamin E, vitamin C, or N-acetylcysteine (NAC), are unable to cross the blood brain barrier (BBB).
This new compound, AD4, is capable of crossing the blood brain barrier.
Successful toxicology studies have been carried out by the well-known clinical research organization, Quintiles.
Studies have been carried out and describe its efficiency in animal models of Parkinson's, MS, haloperidol toxicity, macular degeneration, asthma, beta-thalassemia, and others.
Our Innovation:
Low molecular weight reducing compounds that are able to cross the blood brain barrier (BBB) and provide treatment for neurodegenerative diseases (Parkinson’s, Alzheimer’s), diabetes-related disorders, and ischemic head injuries by the relief of oxidative stress
Key Features:
Unlike all previous drugs, such as NAC that is impermeable or vitamin E that remains in the membrane, the new compound can penetrate the cell membrane and be targeted into the cell.
AD4 is very active, is water soluble, and crosses the blood brain barrier.
AD4 is not toxic (up to 2gr/kg) because it is derived from natural amino acid.
It is significantly (>10-fold) more potent than NAC.
Results of animal trials for macular degeneration (AMD), asthma, Parkinson’s, and multiple sclerosis are very successful and promising.
Toxicology studies for AD4 have been completed.
Development Milestones:
Seeking funding for Phase I clinical studies and ongoing research, and industrial collaboration.
The laboratory holds enough of the compound for immediate use in testing any experimental model.
The Opportunity:
Nervous system neurodegenerative disorders including Parkinson’s and Alzheimer’s diseases as well as diabetes
Conditions of the peripheral tissues, such as acute respiratory distress syndrome, amyotrophic lateral sclerosis, and atherosclerotic cardiovascular disease.
Sales of neurodegenerative drugs reached $18.5 billion in 2009 and are expected to increase 62 per cent to $29.7 billion by 2012.
Successful toxicology studies completed for AD4.
6-2000-278
Israel
